U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
May 30, 2023
Read MoreInnoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
May 23, 2023
Read MoreJournal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors
Apr 27, 2023
Read MoreSulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
Apr 17, 2023
Read More